Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1
Watch recordings from an event which took place on 1st July 2021, in which Dr Tracey Vell MBE, Dr Jaimini Cegla, and Dr Matt Kearney discuss a variety of topics including an overview of NHS England’s CVD agenda, the challenges faced in lipid management, an overview of the NHS England proposed programme to improve lipid management, including the implementation of inclisiran, and some of inclisiran’s clinical trial data.
Cholesterol and cardiovascular disease management
Watch Dr Matt Kearney discuss why cholesterol and cardiovascular disease management is a key focus for NHS England right now.
The proposed launch of inclisiran in England
Watch Dr Tracey Vell MBE discuss the current challenges that primary care faces in lipid management, as well as the introduction of inclisiran into the lipid pathway and the proposed role primary care could play in this.
Inclisiran is currently undergoing a NICE appraisal. The proposed introduction is subject to a positive NICE appraisal.
Introduction to inclisiran
Watch Dr Jaimini Cegla provide an overview of key inclisiran product information, including safety and efficacy data from the Phase III ORION-10 and ORION-11 clinical trials.
Inclisiran is not yet available to prescribe in the UK.
CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; NHS, National Health Service
- Leqvio® Summary of Product Characteristics.